INCY Quote, Financials, Valuation and Earnings

Halozyme Therapeutics has a net margin of 17.07% compared to Incyte's net margin of 45.98%. Incyte's return on equity of 0.81% beat Halozyme Therapeutics's return on equity of 162.37%.

Incyte has a consensus price target of $78.26, signalling upside risk potential of 15.32%. On the other hand Halozyme Therapeutics has an analysts' consensus of $66.11 which suggests that it could grow by 6.2%. Given that Incyte has higher upside potential than Halozyme Therapeutics, analysts believe Incyte is more attractive than Halozyme Therapeutics.

Incyte has a beta of 0.757, which suggesting that the stock is 24.262% less volatile than S&P 500. In comparison Halozyme Therapeutics has a beta of 1.323, suggesting its more volatile than the S&P 500 by 32.293%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Halozyme Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Halozyme Therapeutics pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.2B, which are larger than Halozyme Therapeutics quarterly revenues of $298M. Incyte's net income of $201.2M is higher than Halozyme Therapeutics's net income of $137M. Notably, Incyte's price-to-earnings ratio is 251.33x while Halozyme Therapeutics's PE ratio is 18.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.39x versus 7.93x for Halozyme Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of 17.07% compared to Incyte's net margin of 32.59%. Incyte's return on equity of 0.81% beat Eli Lilly and's return on equity of 80.24%.

Incyte has a consensus price target of $78.26, signalling upside risk potential of 15.32%. On the other hand Eli Lilly and has an analysts' consensus of $1,006.63 which suggests that it could grow by 23.74%. Given that Eli Lilly and has higher upside potential than Incyte, analysts believe Eli Lilly and is more attractive than Incyte.

Incyte has a beta of 0.757, which suggesting that the stock is 24.262% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.817%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.66% to investors and pays a quarterly dividend of $1.50 per share. Incyte pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Incyte quarterly revenues are $1.2B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Incyte's net income of $201.2M is lower than Eli Lilly and's net income of $4.4B. Notably, Incyte's price-to-earnings ratio is 251.33x while Eli Lilly and's PE ratio is 69.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.39x versus 16.33x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Syndax Pharmaceuticals has a net margin of 17.07% compared to Incyte's net margin of -1226.16%. Incyte's return on equity of 0.81% beat Syndax Pharmaceuticals's return on equity of -74.65%.

Incyte has a consensus price target of $78.26, signalling upside risk potential of 15.32%. On the other hand Syndax Pharmaceuticals has an analysts' consensus of $36.14 which suggests that it could grow by 179.1%. Given that Syndax Pharmaceuticals has higher upside potential than Incyte, analysts believe Syndax Pharmaceuticals is more attractive than Incyte.

Incyte has a beta of 0.757, which suggesting that the stock is 24.262% less volatile than S&P 500. In comparison Syndax Pharmaceuticals has a beta of 0.925, suggesting its less volatile than the S&P 500 by 7.546%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Syndax Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Syndax Pharmaceuticals pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.2B, which are larger than Syndax Pharmaceuticals quarterly revenues of $7.7M. Incyte's net income of $201.2M is higher than Syndax Pharmaceuticals's net income of -$94.2M. Notably, Incyte's price-to-earnings ratio is 251.33x while Syndax Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.39x versus -- for Syndax Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 17.07% compared to Incyte's net margin of 31.35%. Incyte's return on equity of 0.81% beat Vertex Pharmaceuticals's return on equity of -3.23%.

Incyte has a consensus price target of $78.26, signalling upside risk potential of 15.32%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $496.78 which suggests that it could fall by -1.58%. Given that Incyte has higher upside potential than Vertex Pharmaceuticals, analysts believe Incyte is more attractive than Vertex Pharmaceuticals.

Incyte has a beta of 0.757, which suggesting that the stock is 24.262% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.414, suggesting its less volatile than the S&P 500 by 58.629%.

Incyte has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Incyte pays -- of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend.

Incyte quarterly revenues are $1.2B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.9B. Incyte's net income of $201.2M is lower than Vertex Pharmaceuticals's net income of $913M. Notably, Incyte's price-to-earnings ratio is 251.33x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Incyte is 3.39x versus 11.88x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.